5/9/2025

Janusmed sex and gender

Janusmed sex and gender – Dorzolamide

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
B B
B B

Dorzolamide

Dorzolamide

Class : B

Show all info

Print

Contact us

  1. Zetterberg M. Age-related eye disease and gender. Maturitas. 2016;83:19-26.

  2. Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci. 2006;47(10):4254-61.

  3. Douglass A, Dattilo M, Feola AJ. Evidence for Menopause as a Sex-Specific Risk Factor for Glaucoma. Cell Mol Neurobiol. 2023;43(1):79-97.

  4. Ye X, She X, Shen L. Association of sex with the global burden of glaucoma: an analysis from the global burden of disease study 2017. Acta Ophthalmol. 2020;98(5):e593-e598.

  5. Xie JS, Kaur H, Tao B, Lee J, Solish D, Kohly R et al. Sex or Gender Reporting in Ophthalmology Clinical Trials Among US Food and Drug Administration Approvals, 1995 to 2022. JAMA Ophthalmol. 2024;142(2):123-130.

  6. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - COSOPT (dorzolamide) [updated 1997-11-02].

  7. Trusopt (dorzolamid). Summary of Product Characteristics. Medical Products Agency Sweden; 2015.

  8. Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I et al. The European glaucoma prevention study design and baseline description of the participants. Ophthalmology. 2002;109:1612-21.

  9. European Glaucoma Prevention Study Group, Pfeiffer N, Torri V, Miglior S, Zeyen T, Adamsons I et al. Central corneal thickness in the European Glaucoma Prevention Study. Ophthalmology. 2007;114:454-9.

  10. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]

  1. Zetterberg M. Age-related eye disease and gender. Maturitas. 2016;83:19-26.
  2. Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci. 2006;47(10):4254-61.
  3. Douglass A, Dattilo M, Feola AJ. Evidence for Menopause as a Sex-Specific Risk Factor for Glaucoma. Cell Mol Neurobiol. 2023;43(1):79-97.
  4. Ye X, She X, Shen L. Association of sex with the global burden of glaucoma: an analysis from the global burden of disease study 2017. Acta Ophthalmol. 2020;98(5):e593-e598.
  5. Xie JS, Kaur H, Tao B, Lee J, Solish D, Kohly R et al. Sex or Gender Reporting in Ophthalmology Clinical Trials Among US Food and Drug Administration Approvals, 1995 to 2022. JAMA Ophthalmol. 2024;142(2):123-130.
  6. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - COSOPT (dorzolamide) [updated 1997-11-02].
  7. Trusopt (dorzolamid). Summary of Product Characteristics. Medical Products Agency Sweden; 2015.
  8. Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I et al. The European glaucoma prevention study design and baseline description of the participants. Ophthalmology. 2002;109:1612-21.
  9. European Glaucoma Prevention Study Group, Pfeiffer N, Torri V, Miglior S, Zeyen T, Adamsons I et al. Central corneal thickness in the European Glaucoma Prevention Study. Ophthalmology. 2007;114:454-9.
  10. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]